Amgen (AMGN): FY25 Q4 earnings call, Feb 3, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 3, 2026 earnings call (FY25 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “Eosinophilic”; 2 quoted, at least 25 words apart.
…continues to advance, with ongoing studies in chronic obstructive pulmonary disease and eosinophilic esophagitis. Where we expect study completion in the second half of this…
…reduced the need for surgery in this population reinforcing its value in eosinophilic disease. TESSPIRE is now the leading therapy for new-to-brand patients amongst allergists…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-02-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-02-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP